Identification and selective depletion of alloreactive T-cells for adoptive immunotherapy.
暂无分享,去创建一个
R. Handgretinger | P. Lang | D. Niethammer | M. Schumm | M. Pfeiffer | A. Willasch | S. Kuçi | E. Rettinger
[1] A. Ganser,et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. , 2009, The Lancet. Oncology.
[2] R. Handgretinger,et al. Molecular monitoring of immune reconstitution after haploidentical stem cell transplantation. , 2008, Current stem cell research & therapy.
[3] T. Klingebiel,et al. T cells for suicide gene therapy: activation, functionality and clinical relevance. , 2008, Journal of immunological methods.
[4] R. Handgretinger,et al. Cellular immune reconstitution after haploidentical transplantation in children. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] R. Handgretinger,et al. Feasibility and Outcome of Reduced‐Intensity Conditioning in Haploidentical Transplantation , 2007, Annals of the New York Academy of Sciences.
[6] Shamsul A. Khan,et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. , 2007, Blood.
[7] R. Krance,et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. , 2006, Blood.
[8] C. Huber,et al. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes , 2006, Bone Marrow Transplantation.
[9] A. Barrett,et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. , 2005, Blood.
[10] T. Klingebiel,et al. Experiences with haploidentical stem cell transplantation in children with acute lymphoblastic leukemia. , 2005, Pathologie-biologie.
[11] J. Hansen. T-cell alloreactivity in hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] R. Champlin,et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. , 2004, Blood.
[13] T. Klingebiel,et al. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. , 2004, Blood reviews.
[14] B. Blazar,et al. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. , 2004, Blood.
[15] J. Gorski,et al. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] J. Michálek,et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. , 2003, Blood.
[17] T. Klingebiel,et al. Megadose transplantation of highly purified haploidentical stem cells: current results and future prospects , 2003, Pediatric transplantation.
[18] C. Perreault,et al. P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. , 2002, Blood.
[19] A. Fischer,et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study , 2002, The Lancet.
[20] N. Chao,et al. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. , 2002, Blood.
[21] C. Huber,et al. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. , 2002, Blood.
[22] A. Hagenbeek,et al. Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] T. Klingebiel,et al. Megadose transplantation of purified peripheral blood CD34+progenitor cells from HLA-mismatched parental donors in children , 2001, Bone Marrow Transplantation.
[24] E. Palmer,et al. Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question1 , 2001, The Journal of Immunology.
[25] A. Zander,et al. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation‐induced antigens (CD25 and CD69) , 2000, British journal of haematology.
[26] B. Fehse,et al. Depletion of alloreactive donor T cells using immunomagnetic cell selection , 2000, Bone Marrow Transplantation.
[27] L. Verdonck,et al. Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft‐versus‐host disease , 1999, British journal of haematology.
[28] J. Gribben,et al. Transplantation of anergic histoincompatible bone marrow allografts. , 1999, The New England journal of medicine.
[29] V. Calcaterra,et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. , 1999, Blood.
[30] H. Prentice,et al. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis , 1999, Bone Marrow Transplantation.
[31] T. Klingebiel,et al. Transplantation of Megadoses of Purified Haploidentical Stem Cells , 1999, Annals of the New York Academy of Sciences.
[32] F. Marini,et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. , 1999, Transplantation.
[33] N. Flomenberg,et al. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation , 1997, Bone Marrow Transplantation.
[34] A. Balsari,et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. , 1997, Cytometry.
[35] J. Hurwitz,et al. Eliminating graft-versus-host potential from T cell immunotherapeutic populations. , 1996, Bone marrow transplantation.
[36] J. Gribben,et al. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. , 1996, Blood.
[37] I. Pastan,et al. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. , 1996, Bone marrow transplantation.
[38] E. Kedar,et al. Prediction by a modified mixed leukocyte reaction assay of graft-versus-host disease and graft rejection after allogeneic bone marrow transplantation. , 1994, Transplantation.
[39] A. Fischer,et al. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. , 1994, Blood.
[40] H. Rammensee,et al. On the nature of peptides involved in T cell alloreactivity , 1991, The Journal of experimental medicine.
[41] M. Ritter,et al. Frequency analysis of cytotoxic T lymphocyte precursors--possible relevance to HLA-matched unrelated donor bone marrow transplantation. , 1988, Bone marrow transplantation.
[42] W. Herzog,et al. Human Cytotoxic T Lymphocytes , 1985, Scandinavian journal of immunology.